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The AAPM Task Group No.43 has provided a standardised dose calculation methodology
that is now the international benchmark for all brachytherapy dosimetry publications and
treatment planning systems (TPS). However, limitations of this methodology has seen the
development of model-based dose calculation algorithms. In 2009, Varian Medical Systems
released Acuros BrachyVision (ABV) which calculates doses by explicitly solving the Linear
Boltzmann Transport Equation. This study aims to investigate the accuracy of ABV dose
calculations in various materials relevant to high dose rate (HDR) brachytherapy with an
Iridium-192 GammaMed Plus source. This study is comprised of two main parts:
1. Construct and validate a monte carlo model of an Iridium-192 GammaMed Plus HDR
source. Energy spectrum and TG43 parameters were simulated and compared to
results collated in studies conducted by Taylor and Rogers [1] and Ballester et al. [2].
2. Calculate and compare doses calculated within a series of phantoms using both GATE
and ABV. Comparison techniques used were; (i) point-to-point profile comparison; (ii)
1D gamma analysis; and (iii) correlation and statistical significance analysis.
Source validation results yielded good agreement with published data. Spectrum and TG43
comparisons showed no major differences, with TG43 comparisons agreeing within 1%.
Point-to-point comparisons showed large differences between GATE and ABV near the
source and in low density materials. 1D gamma analysis pass criteria of 2%/2 mm and
2%/1 mm produced pass rates ranging between 59% - 100% and 45% - 100% respectively.
Correlation analysis Showed statistically there is no significant difference between doses cal-
culated in ABV and GATE. A critical analysis of this study’s results suggest that ABV is
unable to accurately calculate doses in low density materials. Furthermore, spatial distri-
bution of dose near the source is within 2 mm.
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Cancer is a generic term used for a large number of diseases that are caused by normal
cells progressively mutating, uncontrollably proliferating outside their usual boundaries,
invading other areas of the body and spreading to other organs [3]. According to World
Health Organisation statistics, cancer is the second leading cause of death worldwide. In
2018 cancer accounted for 9.6 million deaths, where the most common cases were lung (2.09
million cases), breast (2.09 million cases), colorectal (1.80 million cases), prostate (1.28
million cases), Non-melanoma skin cancer (1.04 million cases) and stomach (1.03 million
cases) [3]. With the development of modern medicine, approximately 50 percent of all cases
can benefit from radiation therapy (RT) [4].
RT is administered through multiple modalities, with the most common modality being
external beam radiation therapy (EBRT) [5]. This modality aims to conform dose to a
treatment volume by directing photons or electrons at a tumour from outside of the body.
An alternative to EBRT is brachytherapy, which for the most part can be referred to as an
internal RT technique. In contrast to EBRT, brachytherapy is capable of maximising dose
to the treatment volume and minimising dose to neighbouring tissues [6] due to the rapid
dose fall off with increasing distance from the seed [7].
Traditionally, Radium-226 (Ra226) was the isotope of choice in HDR brachytherapy appli-
cations. However, it posed major safety concerns as a ruptured Ra226 source would result
in α particles and radon gas being absorbed by nearby tissue and bone. This isotope was
therefore replaced with less hazardous radionuclides such as cobalt-60, gold-198, tantalum-
182, and cesium-137 [8, 9]. In 1958 Iridium-192 (Ir-192) replaced all these isotopes and is
now established as the preferred isotope for high dose rate (HDR) brachytherapy [10].
As brachytherapy sources evolved, so did the dosimetry systems used to plan brachytherapy
treatments. Brachytherapy dosimetry systems established in the early 1900’s included the
Stockholm, Paris, Quimby, Paterson-Parker and Manchester system. Each system denoted
a set of rules that defined the geometric arrangement, source strength and methodology to
obtain a desired dose distribution [11]. Major limitations of early brachytherapy dosimetry
systems are their inability to personalise treatment plans and the lack of consideration for
attenuation and scatter effects [8].
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In practice, scatter and attenuation cannot be ignored. Furthermore, personalised treat-
ments plans are highly desirable. In 1995 the American Association of Physicists in Medicine
(AAPM) Task Group No. 43 published their dosimetry protocol (TG43) which included a
new brachytherapy dose calculation formalism. In contrast to earlier dosimetry systems,
TG43 parameters incorporated measureable quantities that accounted for source-to-source
differences in encapsulation and internal construction. Since the publication of TG43, the
number of source models commercially available increased dramatically, the National Insti-
tute of Standards and Technology (NIST) introduced a new primary standard for air kinetic
energy released per unit mass (kerma) strength and brachytherapy dosimetry literature sub-
stantially grew [12, 13]. In response, the AAPM published an updated version of TG43 and
it was termed TG43U1. Improvements presented in TG43U1 included quantity revisions
and eliminations, guidance on interpolating and extrapolating tabulated parameters, and
corrections for inconsistencies and omissions in TG43 and its implementation. TG43U1 has
provided a standardised dose calculation methodology and is now the international bench-
mark for all brachytherapy sources in brachytherapy dosimetry publications and treatment
planning systems (TPS) [14, 15].
TG43U1 parameters are based on a collection of simulations made in an infinite homo-
geneous water phantom. In clinical applications, where patients and applicators are not
homogeneous and have finite dimensions, these parameters may lead to inaccurate dose cal-
culations. Studies have shown that clinically accepted parameters can be over- or under- by
at least 5% [16]. A possible solution to improve on TG43U1 are model-based dose calcu-
lation algorithms (MBDCAs). Model-based approaches either explicitly simulate radiation
transport or employ mathematical tools such as integration and point spread functions. In
2009, Varian Medical Systems released Acuros BrachyVision (ABV) which calculates dose
by explicitly solving the Linear Boltzmann Transport Equation (LBTE) [17]. LBTE solvers
are in their infancy but are expected to play an important role in future TPS dose calcu-
lation algorithms [18]. A large number of studies compare Monte Carlo (MC) and LBTE
method results as they are both expected to converge to the same solution [19, 20].
1.1 Purpose
The aim of this study was to assess the dose calculation accuracy of ABV in various materials
that are relevant to HDR brachytherapy. This was achieved by,
• Developing and validating a MC model of a GammaMed plus (GMP) HDR brachyther-
apy source
• Making comparisons between MC and ABV calculated doses
MC modelling of the GMP HDR brachytherapy source was done using the Geant4 Ap-
plication for Emission Tomography (GATE). The MC model was validated by comparing
simulated photon spectra and TG43 factors with published data [1, 2, 13].
Once the source model was validated, MC and ABV calculated doses were compared. This
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was done by completing the following tasks: (i) produce identical digital heterogeneous
phantoms in both GATE and ABV, (ii) compare GATE and ABV calculated doses by
comparing profiles that span across all materials in the phantom. Tasks (i) and (ii) were
repeated for all anatomical materials defined in ABV and solid applicator materials stainless




In this chapter I will begin by introducing some fundamental RT concepts that will provide
a knowledge base for later sections. These concepts will include fundamental quantities
and interactions that may occur when ionizing radiation(IR) penetrates through tissue.
Following this, I will discuss the models used to determine the overall effect IR has on a
single cell and a population of cells that make up living tissue. This will help the reader
understand why, if used properly, radiation can be used for cancer treatment. Thereafter,
I will provide an overview of how brachytherapy treatments are delivered. This study’s
main focus is HDR brachytherapy, however later sections will compare HDR and LDR to
provide a holistic view of possible brachytherapy treatments. I will then provide overviews
of TG43 and Varian’s LBTE solver Acuros BrachyVision (ABV). Finally, I will introduce
the Geant4 Application for Emission Tomography (GATE) MC package. Given that there
is some uncertainty around the accuracy of ABV, GATE was used as the primary tool
to investigate the dose calculation accuracy of ABV in various materials relevant to HDR
brachytherapy.
2.1 Fundamental Concepts in Radiation Dosimetry
The primary quantity of concern in RT is absorbed dose, where the International Commis-
sion of Radiation Units and Measurements [21] define it as the mean energy dε imparted by













δs is the sum of all photon track lengths that pass through volume dV.






where dEtr is the sum of the initial kinetic energies of all electrons liberated in a mass dm.
Additionally kerma must be separated into collisional kerma (Kcol) and radiative kerma
(Krad), where both these quantities will quantify the amount of energy lost by ionizing
particles due to collisional and radiative energy losses [8].
Figure 2.1: Schematic of kerma [22].










where µen(E)ρ and φE are the mass energy absorption coefficient and photon fluence respec-
tively, for photons with energy E.
In the process of dose deposition, photons and electrons undergo countless interactions. The
interactions of primary interest in this study are presented in the following sections.
2.1.1 Photon Interaction Processes
Photons penetrating through tissue are attenuated through a countless number of interac-
tions with atoms that make up the medium. Photon-atom interactions may be between the
photon and a loosely bound electron, a tightly bound electron or the nucleus [23].
The probability or cross-section of a photon interacting with an electron or atom is propor-
tional to photon energy hv, and the atomic number Z of the medium. [23]. An iridium-192
source has a max energy of 1.378 MeV [24], which means the dominant photon interactions
will be the Photoelectric effect and Compton Scattering [23]. This is illustrated in figure 2.2
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Figure 2.2: Dominant physical processes of photon interactions in matter as a function of
photon energy and atomic number Z.
The Photoelectric Effect
The photoelectric effect (PE) refers to an interaction between a photon and a tightly bound
electron [25]. The tightly bound electron absorbs the incoming photon, providing it with a
sufficient amount of energy to be ejected from the atom as a photoelectron with a kinetic
energy T,
T=hv− EB (2.5)
where hv is the incident photon energy and EB is the electron binding energy. The ejected
photoelectron will produce a vacancy in the atom which will then result result in the emission
of characteristic x-rays or Auger electrons [23].
The PE cross section (i.e. the probability that a photon will interact with an atom via the
photoelectric effect) is inversely proportional to the third power of the energy and increases






Figure 2.3: Schematic of Compton scattering and the photoelectric effect.
Compton Scattering
Also known as incoherent scattering, Compton scattering refers to the interaction of a photon
with a free electron (Figure 2.3) [23]. The incident photon, carrying energy hv, will impart a
fraction of its energy to the orbital electron and eject it from the atom. The incident photon
will be scattered with a kinetic energy of hv′ at an angle φ, where φ is the angle between the
initial and final propagation directions (equation 2.7). The electron will be ejected with a
kinetic Ek (equation 2.8) at an angle θ, where θ is the angle between the incident direction
and the direction of the recoil electron.
hv’=hv
1










The Compton scattering cross section is expressed using the Klein-Nishina differential equa-
tion (equation 2.10) [8]. Integrating equation 2.10 will provide an expression for the total





































2.1.2 Electron Interaction Processes
The outcome of photoelectric and compton interactions is the liberation of electrons, and it
is these electrons that deposit energy (i.e. dose) to the medium. Electrons will interact with
atomic nuclei and orbital electrons through direct Coulomb interactions. Through these
interactions, they will lose kinetic energy through collisional or radiative losses and change
their direction of travel (i.e. scattered). The energy lost by an electron as it is scattered
through a medium is described by the stopping power of the medium.
Figure 2.4: Schematic for hard, soft and radiative collisions.
Electron interactions are for the most part inelastic and are termed soft, hard and radiative
collisions. The type of collision an electron will have with an atom of radius a is determined
by the impact parameter b, where the impact parameter is the perpendicular distance to
closest approach between the incident electron and the nucleus of the target atom before
an interaction (figure 2.4 [26]). Soft collisions will occur when b»a. The incident electron
will interact with the entire atom and only transfer a small fraction of its energy to orbital
electrons. Hard collisions will occur when b ≈ a. The incident electron will interact with
an orbital electron and in doing so will transfer a large fraction of it energy. Lastly there
are radiative collisions, which occur when b « a. The incident electron will divert from
its original direction and emit a bremsstrahlung photon in the process. The energy of the
bremsstrahlung photon is determined by the magnitude of b.
Stopping Power
The energy lost through hard, soft and radiative are described by the total stopping power
of the medium [23]. The total stopping power is defined as the amount of energy lost
by an electron per unit length and therefore carries units of MeV/cm. Inelastic electron
interactions have two outcomes; (i) energy transfer to orbital electrons; or (ii) electron
scatter resulting in the emission of a bremsstrahlung photon. Given these two outcomes,
the total stopping power can be separated into two components: collisional stopping power,
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which describes the amount of energy transferred to orbital electrons, and radiative stopping
power which describes the amount of energy lost through bremsstrahlung photon emission.
Ultimately, stopping powers will determine the range of an electron in any given medium.













where z is the atomic number of the incident particle, e is the magnitude of electron charge,
n is the number of electrons per unit volume of the medium, m is electron mass, c is the
speed of light in vacuum, β is the speed of the electron relative to c and I is the mean
excitation energy of the medium.
Figure 2.5: Schematic of photon and electron interactions resulting in dose deposition [22].
2.2 Radiobiology
With a basic understanding of dose and how IR deposits energy in a medium, this section
will discuss the overall effect IR has on both a single cell and population of cells.
Photoelectric and Compton interaction inside or nearby a cell will result in interactions with
a cells deoxyribonucleic acid (figure 2.6) [27]. These interactions may inflict single (sub-
lethal) and/or double (lethal) strand breaks [28]. A single cell’s response to these breaks
may include damage repair, apoptosis, mitosis delay, mitotic death, mutation, genomic
instability, transformation, increased radioresistance and induced damage to unexposed cells
surrounding exposed cells via the bystander effect. The probability of inducing cell death
after being exposed to IR is based on the number of double strand breaks [29].
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Figure 2.6: Direct and indirect interactions of IR with DNA resulting in single and double
strand breaks.
Given that a tumour is a population of cells, we must consider them as a whole. The
most common tool used to quantify the effects of IR on a population of cells is the Linear
quadratic (LQ) model [30]. It is a model that describes the relationship between absorbed




where SF is the surviving fraction of cells, D is the dose delivered to the cells, and α and
β are numerical constants that quantify cell radiosensitivity [28, 31]. An example of an LQ
model plot is shown in figure 2.7
Figure 2.7: A linear quadratic model plot [28].
The shape of the LQ plot is determined by the α (linear) and β (quadratic) constants, where
α (linear) and β (quadratic) are constants that vary from tissue to tissue and are presented
in literature as a ratio, α/β.
In general, most tumours will have high α/β ratio and can be termed early responding
tissues, whereas most normal tissues will have low α/β ratio and can be termed late re-
sponding tissues [32]. A comparison of early and late responding tissue using the LQ model
is shown in figure 2.8. This figure highlights that at lower doses, a larger fraction of healthy
tissue cells (i.e. late responding) can be spared than for cancerous tissue cells (i.e. early
responding).
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Figure 2.8: A comparison of early and late responding tissues using an LQ plot [23].
The efficacy of all RT techniques can be expressed using two probabilities: (i) tumour control
probability, TCP, and (ii) the normal tissue complication probability, NTCP [33]. The TCP-
NTCP model is a theoretical model based on a sigmoidal response (figure 2.9). The disparity
between the TCP and NTCP curves are governed by α/β ratios and fractionation regimens
used for treatment [34]. In a clinical situation, an optimal treatment plan will present a
NTCP≤ 5% and a TCP≥ 50% [28].
Figure 2.9: TCP-NTCP model plot.
Given brachytherapy is capable of minimising dose to normal healthy tissue, the disparity
between the NTCP and TCP curves can be pushed further apart. Furthermore, with respect
to the LQ model, SF will approach zero more rapidly for cancer cells as there is minimal
dose deposited in healthy tissue. However, It should be noted that dose to healthy tissue is
only minimised, not eliminated. Therefore measures such as fractionation must be used to
avoid healthy tissue complication. Additionally, fractionation will allow for the SF of cancer
cells to increase their radiosensitivity.
2.2.1 The Four R’s of Radiobiology
The efficacy of fractionation is based on radiobiological experiments that gave birth to the
’Four R’s of radiobiology’. Fractionation allows sub-lethal cell damage to repair, repopu-
late, re-oxygenate and redistribute through the mitotic cell cycle [28]. A summary of
the four R’s of radiobiology are as follows:
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Repair: IR may inflict lethal or sub-lethal cell DNA damage. The ability to repair damage
varies between normal tissue cells and tumour cells [29]. Time between fractions allows
critical healthy tissues to repair and minimise NTCP.
Redistribution: Cells display differential radiosensitivity in different phases of the mitotic
cycle. Radiosensitivity is high in the late G2 and M phase, less radiosensitive during the
G1 phase and most resistant during the S phase [29]. Time between fractions allows for
surviving cells in more radio resistant phases to redistribute into less radiosensitive phases
[28].
Repopulation: Time between fractions will allow repaired tumour and normal tissue cells
to repopulate [28, 29]. Even though this means tumour size will increase in this time, the
LQ model suggests that more tumour cells than normal tissue cells are killed in any given
fraction [25]. Therefore SF will approach zero more rapidly for tumour cells than for normal
tissue cells.
Reoxygenation: Studies have shown that cell radiosensitivty depends heavily on the
oxygen levels within the cell. The reason for this is that the extent of damage caused by free
radicals is proportional to the amount of oxygen in the cell. The presence of oxygen in a cell
that has been exposed to IR will result in free radicals inflicting non-restorable damage to the
chemical composition of the cell DNA [28]. Oxygen levels will vary throughout the mitotic
cycle and the separation between a cell and its nearest blood supply. Normoxic, hypoxic and
anoxic cells refer to cells with high, medium and low oxygen levels, respectively. Eradicating
cells close to a blood supply may result in an increase in blood flow to hypoxic and anoxic
cells. Either from an increase in blood flow and/or redistribution, time between fractions
allows for radiosensitvity to increase and therefore improve the efficacy of the treatment.
2.3 Brachytherapy
A comparison between EBRT and brachytherapy would show that, relative to the TCP-
NTCP model, brachytherapy may achieve superior TCP values [35]. Minimising dose to
healthy tissue and maximising dose to the tumour is highly desirable. A complete compar-
ison covering all variables shows that brachytherapy is best suited for small and localised
tumours at specific anatomical sites. Brachytherapy will often be used to treat cancers in
the head and neck region, breast, cervix, prostate and eye [36].
Given that both LDR and HDR brachytherapy can be used to treat similar types of cancer,
the following section will provide a brief overview of both HDR and LDR, and thereafter




Uniform dose distributions in LDR are achieved by implanting a large number of radioactive
seeds in or near the target volume for long periods of time [37]. Traditionally physicists were
required to manually load all needles and applicators. This was followed by a physician
manually implanting the seeds into their planned locations. In some cases the physician
was also tasked with fixing the applicator in place for the duration of the treatment, where
treatments could last several hours to several days [38].
Radionuclides used in LDR include palladium-103, caesium-131 and iodine-125, with the
most commonly used being the latter. Iodine-125 decays to Tellurium-125 via electron
capture, emits characteristic x-rays with energies of 27.4 and 31.4 keV and has a half life of
59.6 days.
2.3.2 HDR
In contrast to LDR, uniform dose distributions are achieved in HDR by placing a single
source at multiple dwell positions for dwell times as small as 0.1 sec. In preparation for
an HDR procedure, a physician’s task is to insert and stabilize all applicators and needles
required for treatment inside the patient. Transfer guide tubes are used to connect each
needle or applicator to a remote afterloader (RAL) system (figure 2.10 [39]). Following this,
everyone except for the patient will exit the room and treatment will commence.
Figure 2.10: Varian’s GammaMed iX remote afterloader.
Radionuclides used in HDR include Caesium-137, Cobalt-60 and iridium-192, with the most
favoured isotope being the latter [40]. Iridium-192 decays via beta minus decay (95.6%) to
excited states of Platinum-192 and electron capture (4.4%) to excited states of Osmium-192
[9]. It has a half life of 73.8 days and emits photons with an average energy of 380 keV [40].
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2.3.3 HDR Vs LDR
Given that HDR is more commonly used, the following section will present some of the
advantages and disadvantages of HDR when compared to LDR.
Advantages that HDR has over LDR include,
Stable applicator positioning: For intracavitary HDR procedures (e.g. gynaeco-
logical brachytherapy), treatments will typically require the patient to be immobilized
in the lithotomy position using straps and stirrups. This results in less movement of
the patient and the applicator. Studies have reported applicators will move on average
2mm throughout the procedure, where as in LDR on average they will move up to 2
cm [37].
Outpatient treatment: HDR procedures are typically outpatient based, and there-
fore allowing the patient to return home after each fraction of treatment is complete.
Reduced radiation exposure to staff: A major advantage of HDR is that all
involved in the procedure is required to leave the treatment room before patient ra-
diation exposure can commence. With sufficiently shielded walls and doors, radiation
exposure to all personnel are kept to a minimum.
Disadvantages of HDR when compared to LDR include,
Treatment Unit complexity: Compared with traditional LDR processes of man-
ually loading sources, HDR requires more complex equipment. With transfer guide
tubes to guide the source from the RAL to the applicator or needles inside the patient
and treatment software that connects the TPS to the RAL, there are notably more
parameters to consider in HDR when compared to LDR [37].
Radiobiology: The major disadvantage for HDR is a result of its radiobiological
effects. When compared to LDR, HDR inflicts more damage to normal tissue cells
and by doing so reduces the therapeutic ratio [28, 37].
Potential for high radiation exposure: An HDR source has the potential to get
stuck in a position out side of its safe or break off its wire. In any case where the
source is stuck outside its safe, the patient may be exposed to dangerously high levels
of radiation. Furthermore, the physicist who enters the room to remove the source
may potentially receive an exposure above the allowed limits.
2.4 Dose Calculation Algorithms
At the Waikato Regional Cancer Center (WRCC), all brachytherapy treatments are planned
using BrachyVision treatment planning software (BV). BV is a subsystem within Varian’s
oncology information system ARIA and provides a comprehensive tool-set to increase con-
sistency and efficiency in the brachytherapy planning process. BV is divided into different
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applications, each used for specific tasks within the the treatment planning process. Some
of these tasks include, defining patient anatomy, planning applicator or source positions and
computing dose [41]. In BV, the latter can be achieved using either the TG43 formalism or
Acuros (ABV). The TG43 formalism calculates dose using multitude of predefined terms,
where as ABV calculates dose by solving the Linear Boltzmann Transport Equation. The
following sections will provide an overview of the TG43 formalism and how ABV solves the
LBTE.
2.4.1 AAPM TG43 Dose Calculation Formalism
In 1995, the American Association of Physicists in Medical Physics Task group No. 43
published their report on dosimetry of interstitial brachytherapy sources [9], and is now
globally referred to as TG43. Presented in this document was a recommended dose calcu-
lation formalism that progressively became the worldwide standard for brachytherapy dose
calculations [12, 15]. It also provided dosimetry data sets for commercially available sources
at the time of its publication. In 2004, the AAPM published a revised AAPM protocol for
brachytherapy dose calculations [12] and was later termed TG43U1. TG43 protocol was
updated for the following reasons:
• To eliminate inconsistencies and omissions in the original TG43 document.
• To recommend consensus datasets for iodine-125 and palladium-103 source models
introduced before and after the publication of the TG43 protocol in 1995.
• To develop guidelines for experimental and MC determination of reference-quality dose
distributions.
• To provide additional AAPM recommendations for acquiring dosimetry data and clin-
ical implementation.







where r is the distance to the point of interest in centimetres and θ is the angle with respect
to the longitudinal axis of the source. The reference point to which the formula is normalised
to is denoted by (r0, θ0) and lies on the transverse bisector of the active core of the source
at a distance of 1 cm, i.e., r = 1 cm and θ = 90 deg. TG43 and TG43U1 assumes all seeds
and dose distributions surrounding a source are cylindrically symmetrical, with the origin
of the co-ordinate system at the center of the active core.
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Figure 2.11: TG43 and TG43U1 dosimetry calculation co-ordinate system.
The first term in equation 2.14, SK, is the air kerma Strength (AKS). AKS was first intro-
duced in TG-32 Report No. 21 and is presented in TG43 as a measure of source strength.
TG43 defines the air kerma strength as the product of the air kerma rate, k̇, at the cal-
ibration point along the transverse bisector of the source in free space and the square of
the distance, d, between the calibration point and the origin [42]. TG43U1 proposed minor
revisions to this definition by explicitly stating experimental set up conditions and exclud-
ing photons that would increase air kerma rate without significantly contributing to dose at
distances greater than 1 mm in tissue [12]. With these revisions, the current equation to be
used for calculating air kerma strength is,
Sk=k̇δr2 (2.15)
where δ is the cut off energy. Air kerma strength carries units of cGycm2h−1. However, for
simplicity, TG43 and TG43U1 denotes the units of SK with the symbol U.
1U=1cGycm2h−1=1µGym2h−1 (2.16)
The second term in equation 2.14, Λ, is the dose rate constant (DRC). This term is defined
as the dose rate in water to a point 1 cm away from the source along the transverse axis
(i.e. r = 1 cm, θ = 90 deg) for a unit air kerma strength source. It is an absolute quantity





The dose rate constant includes effects due to radionuclide distribution in the source, source
geometry, encapsulation, filtration and scatter due to the capsule and the phantom. Λ has
units of cGy h−1U−1.





, is a ratio of the geometry function calculated
at both the reference point and the point of interest. The geometry function provides
an effective inverse square law correction for a line source and neglects all scatter and
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absorption effects. For a point and a finite line source, the geometry function at all points
can be modeled using the following equations,
GP (r, θ)=r−2 (2.18)
GL(r, θ)=

β/(Lr sin θ) if θ 6= 0o
(r2 − L2/4)−1 if θ=0o
(2.19)
where β is the angle between two hypothetical lines starting at each end of the source and
meeting at the point of interest, P(r,θ), and L is the active length of the source. TG43U1
recommends consistent use of the line source approximation models when evaluating 2D
dose distributions.
The fourth term in equation 2.14, gL(r), is the radial dose function. This function is a
relative quantity that accounts for scatter and absorption effects across the transverse plane
(i.e. θ0=π/2) caused by the medium and the encapsulation around the active core. TG43U1
made a minor revision to the radial dose function formalism, and added the subscript "X".
This subscript was used to indicate whether a line source, "L", or a point source, "P",
approximation model was used to calculate the geometry function. The radial dose function





Consensus source data will typically present radial dose function values in tables for discrete
values of r to allow for interpolation between data points. In contrast, some commercial
treatment planning systems (e.g Vitesse and brachyvision) will fit a fifth order polynomial
to the tabulated data [12].
Finally, the fifth term in equation 2.14, F(r,θ), is the 2D anisotropy function. This function
describes the angular variation of dose due to self filtration, oblique filtration of primary
photons through the encapsulating material and scattering of photons in the surrounding
medium. The dose rate is lowest along the source axis due to the increased self absorption






The TG43 formalism has provided a worldwide standard for brachytherapy dose calculations
for may years. However, The design of this formalism does not accommodate for real patient
geometry and materials introduced by the patient and applicators that may be used for




The Acuros BV (ABV) dose calculation algorithm was developed from a desire to provide
a rapid and accurate alternative to MC simulations that is capable of accounting for finite
patient dimensions, anatomical material differences and applicator materials. ABV achieves
this by deterministically solving the Linear Boltzmann Transport Equation (LBTE). LBTE
is a mathematical model that describes radiation conservation as energised particles traverse
through a medium [18].
In the context of Ir192 HDR brachytherapy, secondary electrons ranges are much smaller
that the voxel calculation size. Furthermore, the fraction of energy lost through radia-
tive processes of charged particles is negligible. Therefore ABV does not track secondary
electrons and employs the kerma approximation, D=Kcoll ≈ K [17].
In order for ABV to calculate kerma, it must first solve the LBTE to determine the fluence.
Photon fluence through a voxel has three components: (i) primary fluence (ii) fluence from
photons being scattered in the surrounding voxels, and (iii) photons that interact inside the
voxel and are either absorbed locally or scattered. The three components that contribute
to the total fluence are accounted for in the general form of the LBTE,










Ψ(~r,E, Ω̂) is the angular photon fluence,
qscatter(~r,E, Ω̂) is the photon scattering source,
qprimary(E, Ω̂) is the primary photon source,
~r is the position of interest,
~rP is the source position,
E is the energy of the particle,
Ω̂ is the particle motion direction,
δ(~r− ~rP) is the Dirac delta function between the source location and the position of interest,
and
σt is the macroscopic total cross section at the position of interest, σt(~r,E).
Under charged particle equilibrium (CPE), the primary fluence can be analytically solved
using ray-tracing [15, 17, 18, 43]. The scatter component however, cannot be solved ana-
lytically. The scatter component is a function of angular fluence and can be expressed as a







σs(~r,E’→ E, Ω̂ · Ω̂′)Ψ(~r,E’, Ω̂′)dΩ̂′dE’ (2.23)
where:
σs(~r,E’→ E, Ω̂ · Ω̂′) is the macroscopic differential scatter cross section.
The macroscopic differential scatter cross section can be expanded in Legendre polynomials,
PL=µ0, where µ0=ψ · ψ′, and the angular fluence is expanded into spherical harmonics,
L=3 for within group scattering and L=2 for out of group scattering [17, 18]. Applying
these expansions replaces the integrals with discrete summations, which make the scatter










σs,l(~r,E’→ E)φl,m is the macroscopic differential equation.
φl,m(~r,E’) is the spherical harmonic moments,
Yl,m(Ω̂) is the spherical harmonic functions, and
l,m are the angular indices.
ABV solves the resulting form of the LBTE by discretizing its six variables: three variables
in space, (x, y ,z), using finite difference or finite element methods, two variables in angle,
µ, η, ξ=
√
1− µ2 − η2, using discrete ordinates method, and energy, E, using the multigroup
approximation [17, 18, 44]. ABV’s solution to the LBTE provides the angular and energy
dependent photon fluence at every spatial degree of freedom within the computational do-















D(~r) is the dose at position ~r,
ρ(~r) is the density at position ~r,




p,g (~r)φcollidedg (~r) is the total scalar fluence at position ~r.
Generally there are two methods that can be used to produce an LBTE solution. The first
being explicitly solving the LBTE (i.e. ABV) and the second being MC. With sufficient
refinement, both methods should converge on the same solution.
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GammaMed Plus Source
Sources used in ABV are modelled as effective sources, where they are represented as one or
more point sources located on the surface of the true source geometry. Photons are emitted
from each point source with the energy and angular intensity that best represents where
they are located relative to the true geometry of the source. Given that effective sources are
a multitude of point sources, the LBTE must be solved for each point source located at ~rp
and summed to give the total fluence at position ~r. The spectrum of photons emitted from
each point source are binned into 37 groups and 10,000 angles.
The source of interest in this study is the GammaMed Plus HDR (GMP) source. Figure
2.12 shows the dimensions, in millimeters, and materials used to model the GMP source
[45]. The core of the GMP source is a 3.5 mm long solid iridium cylinder with a diameter of
0.6 mm. Encapsulating the source core is a hollow AISI 316L stainless steel cylinder, with
a density of 8.03 g/cm3, an outer diameter of 0.9 mm and a truncated cone end. Source
encapsulation is directly attached to an AISI 304 stainless steel cylinder, with a density of
5.6 g/cm3, a diameter of 0.9 mm and a length of 2 mm. All effective sources in ABV are
modelled with a source wire length of 2 mm. The reason for this is that a source wire length
of 2 mm is the maximum length where significant bending of the wire doesn’t occur [17].
Figure 2.12: GammaMed Plus source geometry.
Evenly distributed through the active core of the GMP source is the radioisotope iridium-
192 (Ir192). Ir192 has a half life of 74 days and decays into platinum-192 via electron
capture (EC) 95.13% of the time and β− into Osmium 192 the remaining 4.87%. The
complicated photon spectrum ranges from 7.82 keV to 1.378 MeV and has an average energy
of approximately 370 keV [9, 24]. Simulations for this study were performed using the Ir192
spectrum provided by the NNDC [46]
2.5 Monte Carlo
The MC method can be defined as a numerical method used to solve equations and calculate
integrals through repeated random sampling [47]. MC simulations are capable of modelling
physical processes and systems where the probability of different numerical results are not
easily predictable. Furthermore, it is a tool capable of providing results for problems that
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cannot be attained analytically or experimentally. MC has many applications and is consid-
ered the gold standard for attaining numerical results when modelling radiation transport
[19, 48]. It doesn’t explicitly solve the LBTE, rather it indirectly produces an LBTE solution
[17].
2.5.1 Random Number Generators
Random sampling is achieved in MC through random number generation. This is accom-
plished using a random number generator algorithm (RNG). By definition, computers are
unable to produce numbers that are truly random and are therefore termed pseudorandom
numbers [47]. RNG’s will typically produce a uniform distribution of numbers between 0
and 1, either as large sequences of predetermined numbers or on the fly. Together with cross
section modelling, these numbers will be used to determine the outcome of a particle inter-
action. Given that the number of histories executed in RT simulations are on the order of
billions, the ideal RNG will have an extremely long period. This is to avoid any correlation
in MC results [47].
2.5.2 Monte Carlo Statistics
Uncertainties presented in this study will be expressed using the methods recommended in
the guide to the expression of uncertainty in measurement (GUM) [49]. The GUM defines
the quantity to be measured as the measurand Y, and its associated standard uncertainty
as the standard deviation u. In most cases, the best estimate of the measurand, denoted as
y, will not be directly measured, and will be determined from N input estimate quantities
xN through a functional relationship f, where each input estimate will have its own standard
uncertainty. Therefore the standard uncertainty of each input quantity must be combined
to determine the combined standard uncertainty in y.










Uncertainties are separated into two types, type A and a type B. Type A uncertainties
are evaluated using statistical methods, and type B uncertainties are evaluated by any
means other than statistical analysis. In the context of absorbed dose measurements, GATE
simulations provide the experimental standard deviation for each voxel. Given that the MC
method is a stochastic process, the uncertainties provided by GATE are type A uncertainties.
The uncertainties determined in GATE are calculated using the history-by-history method

















where Sd̄k is the experimental standard deviation of the dose deposited in voxel k, dk,i is the
dose deposited in voxel k by an independent history i and N is the total number of incident
photons.
2.6 Geant4 Application for Emission Tomography (GATE)
MC packages frequently used in medical physics applications include EGS4, EGSnrc, PENE-
LOPE, MCNP, Geant4 and Gate. In this study, the MC package used was GATE and there-
fore the following sections will discuss the structure of GATE and the macro files executed
in GATE, tools used to interact with GATE simulations, variance reduction techniques
available in GATE and monte carlo statistics.
GEANT4 is a MC code that contains comprehensive physics models, libraries and tools
capable of modelling a variety of complex scenarios [52]. Though it is versatile, it is a very
complex code to use. Efficient use of GEANT4 requires a considerable level of experience
with object-oriented codes written in C++ programming language. For new users to gain
such a level of experience can be very time consuming. It is for this reason that applications
such as GATE have been developed.
Figure 2.13: Layered architecture of GATE.
GATE is an advanced open source application software developed by the international Open-
Gate community. Well known for its widespread use in imaging simulations, GATE has also
shown its potential when used in dosimetry applications [53]. The GATE application encap-
sulates all the complex functionalities of GEANT4 while providing a user friendly interface.
It is a multilayered structure with the base of the structure being the Geant4 MC code
(Figure 2.13) [54]; The core layer defines the main tools and features; The application layer
is a subset of tools and features defined in the core layer; The user layer is the layer that
end-users can interact with and call upon the functionalities of GEANT4 to simulate their
experiments.
Gate simulations are run by executing primary macro files. Macro files contain a list of
commands defining each component required to successfully run a simulation. In addition,
secondary macro files may be written and executed within the primary macro file. The basic
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structure of a main macro file is shown in Table 2.1 [55].
Table 2.1: Basic structure of a primary macro file used in radiotherapy Gate simulations.
[ Verbose macro ]
[ Visualisation macro ]
1 - Geometry description macros
2 - Phantom description macros
3 - Physics related macros
4 - Output set up macros
/gate/run/initialize




In order to draw information from a simulation, the user must include actors in their macro
files. Actors are tools that allow the user to interact with their simulations by collecting
information (e.g. absorbed dose, number of particles entering a volume etc.) or modifying
the behaviour of their simulations (e.g. particle filtration/killing) [56].
Some actors, such as the DoseActor, will store information (i.e. energy deposited, dose,
uncertainty) in a 3D scoring matrix. Within the main macro, the actor must be attached to
a volume of interest. The user is able to set the size, resolution (i.e. voxel size) and position
of the 3D scoring matrix relative to the origin of the volume of interest. It should be noted
that, if the volume of interest is larger or smaller than the 3D scoring matrix, information
will only be scored for hits occurring within their overlapping regions.
2.6.2 Variance Reduction Techniques (VRT’s)
Variance informally describes how spread out a series of numbers are from their mean value.
The variance in MC simulation results is proportional to 1/N, where N is the number of
histories produced in the simulation [47]. The most obvious way to decrease the variance
would be to increase the number of histories, although this will also increase simulation
times. A major disadvantage of the MC method is that it can be very time consuming.
Therefore, algorithm techniques such as variance reduction techniques are essential as they
optimise transport parameters while maintaining a high level of accuracy. Variance reduction
techniques used in this study include range/energy cuts and kerma approximation.
Range/Energy Cuts
Range/ energy cuts is a technique that terminates particle tracking once any given particle
has gone below an energy or range threshold set by the user. Without range and energy
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cuts, particles are tracked until they reach the system boundary (i.e the world) or deposit
all of their energy.
variables to consider when selecting range and energy thresholds include,
• are the particle ranges much smaller than the calculation volume, and therefore deposit
all of its energy locally, and
• is the energy of the particle large enough to significantly contribute to the dose
When a particle is stopped due to its energy or range falling below the set thresholds, all of
its energy is deposited locally [56].
Kerma approximation
Within the context of brachytherapy, the energy released by photons is absorbed directly
in the neighbourhood of the photon ray [47]. Therefore, secondary electrons do not need to
be tracked. As a result, kerma can be used as an approximation of dose. Photon fluence





where L is the distance travelled in the voxel between successive collisions. Following on










The primary purpose of this study was to assess the dose calculation accuracy of ABV in a
variety of materials relevant to HDR brachytherapy. The following sections will present the
methodologies used to achieve this.
First I will outline the settings used to build a GMP source model in GATE. These settings
will include GMP source specification, physics, RNG’s and VRT’s. I will then present
the phantom that was designed and modelled for making GATE versus ABV comparisons.
Following this, I will detail the methodology used to verify the source model. Thereafter I
will present the data analysis tools used to make GATE versus ABV comparisons.
3.1 GATE Setup
The primary tool used in this study was the GATE MC toolkit V8.0, with the base of this
toolkit being the GEANT4 environment (V10.4). Both GEANT4 and the GATE tool kit
were installed and built on a PC with an Intel R© Xeon R© E5620 processor. This processing
unit is a 4 core processor with 2.4 GHz processor base frequency. Using a single processor
resulted in simulation times ranging between 2 - 5 days.
GATE was used to model Varian’s Ir192 GammaMedPlus HDR (GMP) source. Geometry
and material information used to model this source was taken from work done by Lopez et
al. 2.12 [45]. A screenshot of the GMP source modelled in GATE is given in figure 3.1.
Following recommendations provided by Rivard et al. [24], the Ir192 spectrum attached
to the active length of the source was that provided by the National Nuclear Data Center
(NNDC) [46].
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Figure 3.1: GMP source modelled in GATE.
NNDC’s Ir192 spectrum has a maximum energy of approximately 1.38 MeV. Therefore the
primary interactions to be considered when modelling the GMP source are Compton scat-
tering and the photoelectric effect. Before the release of GATE V7.0, user guides instructed
users to individually list the interaction processes of interest. However, since the release
of GATE V7.0, developers highly recommend using the predefined physics lists, inherently
available in GEANT4. Therefore for this study the emstandard package was used. For Ir192
energies, this package calculates cross sectional data using the Klein-Nishina and Livermore
models for photon interactions, and the urban model for electron interactions [58].
GATE V8.0 has three different RNG’s available for use, the Ranlux64, the James Random
and the Mersenne Twister (MT). Studies have shown that of these three generators, the MT
generator is favoured because of its extremely long period of 219937−1 [59, 60] and therefore
was used in this study. In addition to MT’s extremely long period, the MT generator
preregenerates a pool of numbers to be used instead of generating random numbers on the
fly, and as a result reduces simulation times [47].
Simulation times were further reduced by using VRT’s such as energy cuts and kerma
approximators. Following Perez et al. recommendations, a photon cut energy of 10 keV
was used [13]. A cut-off energy of 10 keV will reduce simulation times while maintaining
simulation accuracy. Perez et al. also provides recommendations for the use of kerma
approximators, which will be provided in a later section.
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(a) (b) (c)
Figure 3.2: (a) Digital phantom design. (b) Digital phantom modelled in GATE. (c) Digital
phantom modelled in ABV.
3.2 Digital Phantom
Dose calculation comparisons were made using a simple digital phantom with interchange-
able slabs (figure 3.2). This phantom is comprised of 4 individual slabs of material, where
BS1 and BS2 are 101 mm x 101 mm x 101 mm and ’Source slab’, ’Pink’ and ’Yellow’ are
101 mm x 101 mm x 11 mm. The dose calculation grid across the entire system is made up
of 1 mm x 1 mm x 1 mm voxels . These dimensions were selected so that the center of each
slab coincided with the center of a voxel.
With the source centered in the ’source slab’, this system is used to produce 6 individual
phantoms with varying materials where dose was measured using the standard DoseActor.
Presented in table 3.1 are the materials assigned to each slab for each phantom setup. All
material composition data is given in appendix A.1.5.
Table 3.1: Phantom material combinations used for GATE vs Acuros BV comparisons.
Phantom material combinations
Phantom BS1 Pink Source Slab Yellow BS2
1 water Air water Peek water
2 water Bone water Cartilage water
3 water Lung water Titanium water
4 water Muscle water Adipose water
5 water Water Stainless steel water water
6 water Water PMMA Water water
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3.3 Source Validation
Before dose comparisons can be made between GATE and ABV, the GMP source modelled
in GATE must be validated. This is to provide evidence that what is being simulated is a
true reflection of what happens in the real world. Therefore simulated photon spectra and
TG43 factor results were compared with well validated published data.
Recommended TG43 Consensus data for the GMP source was published by Perez et al.
in their report “Dose calculation for photon-emitting brachytherapy sources with average
energy higher than 50 keV: report of the AAPM and ESTRO” [13] and includes results
published by Ballester et al. [2] and Taylor and Rogers [1]. Simulations in this study for all
TG43 parameters were set up according to recommendations provided by Perez et al. [13],
Lopez et al. [45] and Thiam et al. [61]. Recommendations for calculating TG43 parameters
include,
• Minimise volume averaging effects to <0.1% when using the collisional kerma approx-
imator by configuring voxel sizes to be 0.1 mm x 0.1 mm x 0.1 mm for distances in
the range of rsource ≤ 1 cm, 0.5 mm x 0.5 mm x 0.5 mm for distances in the range of
1 cm < r ≤ 5 cm, 1 mm x 1 mm x 1 mm for distances in the range of 5 cm < r ≤ 10
cm and 2 mm x 2 mm x 2 mm for distances in the range of 10 cm < r≤ 20 cm
• Simulations should be computed in a phantom that approximates full scatter condi-
tions of an unbounded phantom. For Ir192, a spherical phantom with a radius of R
= 40 cm should be used
• When feasible, type A uncertainties should be kept below <0.1%
With the exception of AKS and photon spectrum measurements, where the EnergySpectru-
mActor was used, all TG43 dose measurements were acquired using GATE’s kerma approx-
imator, the TLEDoseActor. The number of histories for all TG43 measurements was set to
2.1 x 109.
3.3.1 Energy Weighted Spectrum
With the GMP source located in the center of a vacuum, the EnergySpectrumActor was used
to detect and store all photons emitted from the source (including the source wire). The
EnergySpectrumActor builds a histogram based on the energy range and bin width defined
by the user. In this study, the energy range and bin width was set to 0.001 - 1.38 MeV and
0.001 MeV respectively
Spectrum results from this study were compared to Taylor and Rogers results, where spec-
trum results were presented in their study as an energy weighted spectrum. Therefore the









(∆E · R) (3.1)
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where Ej is the energy at the middle of a bin, Ei is the energy of the ith photon escaping
the the source with energies between Ej ±∆E/2, ∆E is the bin width and R is the sum of
the energies of all photons detected.
3.3.2 Air Kerma Strength Sk and Dose Rate Constant Λ
Following TG43U1, Γ was calculated by dividing the dose rate at the reference point (Ḋ(1,
π/2)) in a liquid water phantom by the AKS (equation 2.17), where AKS is the air kerma
rate multiplied with the square of the distance from the origin to the point where the air
kerma rate was measured (equation 2.15).
Assuming isotropic emission around the source in the transverse plane, Ḋ(1, π/2) was cal-
culated as the mean dose rate scored at four representations of the reference point around
the source,
Ḋ(1, π/2)=
Ḋ(1, π/2, 0) + Ḋ(1, π/2, π/2) + Ḋ(1, π/2, π) + Ḋ(1, π/2, 3π/2)
4N
(3.2)
where N is the total number of histories executed.







where ΦE and µenρ (E) are the fluence and the mass energy absorption coefficient in air for
photons with energy E respectively. Within the context an 192Ir source and the materials







(1− g) ≈ µtr
ρ
(3.4)
With the source origin positioned at the center of a spherical vacuum, the fluence was
measured by attaching an EnergySpectrumActor to a thin cylindrical volume with an inner
diameter of 50 mm and a width of 1 mm. The output spectrum was configured to store
all photons between 0.001 MeV and 1.379 MeV into bins 0.001 MeV wide. Given that
the output spectrum is a histogram, equation 3.3 was approximated using a Riemann sum
approximation [62]. Therefore the air kerma rate at a distance of 5 cm from the source due








where Φi is the fluence due to the photons in the ith bin, ∆E is the bin width, µenρ (i∆E) is
an approximation of the mass energy absorption coefficient for all photons in ith bin1, N is
1Values for µen
ρ
(i∆E) were obtained by interpolating data published by NIST [63]. See figure A.1 of
appendix A.2.1
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the total number of histories and 1.602× 1013 is the conversion factor to convert MeV/g to
joules/kg.
Figure 3.3: Ring geometry definition.
3.3.3 Radial Dose Function, g(r)
Following TG43U1, the radial dose function only requires measurements in the transverse
bisector plane of the source (equation 2.20). Once again assuming isotropic emission around
the source in the transverse plane, absorbed dose was measured using thin rings centred
around the source origin. Dose measurements were produced for r = {0.2cm, 0.25cm,
0.5cm, 0.75cm 1cm, 1.5cm, 2cm, 3cm, 4cm, 5cm, 6cm, 7cm, 8cm, 10cm} using the cylinder
dimensions shown in table A.1 of appendix A.2.3. Once the dose deposited in each ring was








where N is the total number of histories. TG43U1 recommends consistent use of a line-
source approximation when deriving both the radial dose and anisotropy functions. It is for
this reason that the geometry function values shown in figure A.2 of appendix A.2.2 were
calculated as per equation 2.19.
Figure 3.4: Anisotropy measurement setup.
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3.3.4 2D Anisotropy Function, F(r,θ)
The system used to produce the required measurements is illustrated in figure 3.4. For any
given value r0, the 2D anisotropy function describes the variability in the dose distribution
over 0 ≤ θ ≤ π. Therefore to calculate the anisotropy function for a single value of r0,
absorbed dose measurements at different points along the long axis of the source must be






where n represents the total number of rings on either side of source origin. Anisotropy
function values were produced for r0 = {4mm, 6mm, 10mm, 35mm, 60mm, 100mm} using
the cylinder dimensions shown in tables A.2 - A.7 of appendix A.2.4. It should be noted
that at 0 and π2 , dose measurements were produced using cubes instead of rings. Once the





where N is the total number of histories.
3.4 Monte Carlo Calibration factor
The maximum number of histories executable in a single GATE simulation is approximately
2.1 x 109. For a 10 Ci source, 2.1 x 109 reflects a real dwell time of less than 0.01 sec. Given
that the absolute minimum dwell time that is accepted in BrachyVision is 0.1 sec [64], a
single GATE simulation executing 2.1 x 109 will not suffice. Multiple simulations can be
executed to generate enough data to reflect an acceptable dwell time but will be very time
consuming. This can be avoided by producing a MC calibration factor that can accurately
convert GATE doses into doses that reflect dwell times larger than 0.1 sec.
A MC calibration factor was produced using the system described in section 3.2. With
water as the material assigned to each slab and a source centered in the phantom with its
long axis orthogonal to the y axis, the dose rate at y = 1 cm and y = -1 cm were estimated
for a dwell time t (ABV) and histories N (GATE). Taking the average of these estimations,





where ḊABV(r0, θ0), ḊGATE(r0, θ0) and f carry units of Gy/seconds, Gy/history and histo-
ry/second respectively. This calibration factor was then applied in the following equation
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to convert GATE doses to doses that reflect practical dwell times in BV,
DX(r, θ)=f ·
DGATE(r, θ) · t
N
(3.11)
where X represents the algorithm used to estimate the dose at r and θ (i.e. TG43 or ABV),
t is the planned dwell time, DGATE(r, θ) is the dose estimated at r and θ in GATE, N is the
number of simulated histories and f is the MC calibration factor.
3.5 Comparison Tools
Using the phantom setup described in section 3.2, GATE versus ABV dose to medium
estimations were compared, with GATE being used as reference. In order to make confident
conclusions about the accuracy of ABV, the following comparison techniques were used:
• Point-to-point profile comparisons
• 1D Gamma analysis
• Correlation and statistical significance analysis
Gamma Analysis
The gamma analysis technique compares all measurement points against the calculated dose
distribution and assigns each point a quality index number γ. It is a pass-fail test that is
based on discrete point dose differences and distance-to-agreement (DTA) tolerances (e.g
δD=2%, δd=1mm respectively) [65, 66]. The magnitude of γ is determined by the distance
between the measurement point and the calculated point that exhibits a dose within the
specified point dose difference tolerance ∆D. A geometrical representation that considers
the DTA and point dose difference tolerances of a 1D gamma analysis is shown in figure 3.5
[65, 67], where the circumference of the circle is defined by Equation 3.12.











∆r(rR, r)=|r− rR| (3.13)
and
∆D(rR, r)=D(r)−DR(rR) (3.14)
Figure 3.5 illustrates that the pass fail criteria is based on whether or not DE lies within the
circumference of the circle defined by ∆d and ∆D. Taking the right hand side of equation










∆r(rR, rE)=|rR, rE| (3.16)
and
∆D(rR, rE)=DE(rE)−DR(rR) (3.17)
From equation 3.5 we can then determine the quality index at rR as,
Γ(rR)=min{Γ(rR, rE}∀{rE} (3.18)
where the pass-fail criteria becomes,
• γ(rR) ≤ 1, calculation passes
• γ(rR) >1, calculation fails.
One dimensional local gamma analyses were executed in this study using a Matlab code
provided by M. Geurts [68]. Gamma analysis pass criterion used in this study was δr=2mm
δD=2% and δr=1mm δD=2% with a pass rate of ≥ 99%.
Correlation Analysis
Correlation analysis is a statistical method used to analyse the strength of a relationship
between two quantitative variables x and y. The correlation analysis method used to cal-
culate the correlation between x and y in this study was the Pearson correlation coefficient
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where n is the number of individuals. Illustrated in figure 3.6 are cases where x and y
demonstrate strong correlation (i.e r = 1 and r = -1) and no correlation (i.e. r ≈ 0). The
degree of correlation between variable x and y is determined by how close r is to 1 or -1.
A positive correlation coefficient means that x and y are positively correlated. Conversely,
a negative correlation coefficient means that x and y are negatively correlated.
Figure 3.6: scatter diagrams for r = 1; r = -1; and r ≈ 0.
All Pearson correlation coefficients presented in this study are accompanied with their asso-
ciated P-value. The purpose of a P-value is to firstly indicate the probability of encountering
an alpha error and secondly to indicate whether or not the null hypothesis can be rejected
or accepted [71]. The null hypothesis in this study is that statistically ABV and GATE
calculated doses are significantly different. The null hypothesis can be rejected if P ≤ α,






4.1.1 Energy Weighted Spectrum
Presented in figure 4.1 is a comparison of the energy weighted photon spectrum produced
in this study with that published in Taylor and Rogers TG43 Parameter database for
brachytherapy. In general there is good agreement, with both sets of data giving spikes
for the same energies.

















Energy Weighted Spectrum Comparison
Gate
Taylor and Rogers
Figure 4.1: Energy weighted spectrum comparison between results produced in this study
and work done by Taylor and Rogers.
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4.1.2 TG43 Comparisons
Source validation is typically achieved by comparing simulated results with both exper-
imental and published data. However, given that TG43 data for the GMP source is well
validated within the medical physics community, simulated results were only compared with
published data. Consensus TG43 data for the GMP source was published by Perez et al.
[13] and was therefore used as the primary reference for comparisons.
Air KERMA Strength Sk and Dose Rate Constant Λ
Presented in figure A.1 of appendix A.2.1 is a plot of energy vs mass energy absorption coef-
ficient for air [46] with their corresponding best fit equations. To reduce uncertainties when
interpolating between data points, all best fit equations were determined such that their
corresponding determination coefficients (r2) were close to 1. This study’s best estimation
of Sk(1cm, π2 ) was,
Sk = 9.027 x 10−12 cm2 cGy history−1
With this this value, the DRC could be estimated and is presented in table 4.1. With
a combined standard uncertainty of 2.17%, this study’s best estimate of the DRC is in
excellent agreement with consensus data.
Table 4.1: MC and consensus DRC comparison.
GATEΛ (cGy h−1 U−1) consensusΛ (cGy h−1 U−1) Difference
1.123± 0.033 1.117± 0.004 0.57%
Radial Dose Function
Radial dose function values produced in this study are presented in table 4.2 and figure 4.2.
All data points are in agreement within 1% with consensus data and Taylor and Rogers
results. The combined standard uncertainties for all data points are no larger than 0.06%
(k=1). Error bars are included in figure 4.2 but are too small to be evident on the plot.
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Figure 4.2: Radial dose function comparisons between Perez eat al., Taylor and Rogers, and
this study’s results.
Table 4.2: Discrete point comparisons of this study’s radial dose function values with con-
sensus data.
r(cm) GATEGL(r) U (k=1) ConGL(r) difference T&RGL(r) difference
0.20 0.992 0.05% 0.998 0.61% 0.991 -0.08%
0.25 0.994 0.05% 0.997 0.36% 0.993 0.06%
0.50 0.996 0.06% 0.996 0.06% 0.996 -0.06%
0.75 0.998 0.06% 0.998 -0.05% 0.998 0.01%
1.00 1.000 0.06% 1.000 0.00% 1.000 0.00%
1.50 1.002 0.05% 1.003 0.10% 1.004 0.16%
2.00 1.004 0.06% 1.006 0.13% 1.007 0.23%
3.00 1.007 0.06% 1.006 -0.09% 1.009 0.22%
4.00 1.006 0.06% 1.004 -0.21% 1.008 0.23%
5.00 1.003 0.06% 0.999 -0.34% 1.005 0.24%
6.00 0.996 0.06% 0.993 -0.34% 0.999 0.29%
8.00 0.974 0.06% 0.968 -0.57% 0.976 0.23%
10.0 0.941 0.06% 0.935 -0.61% 0.943 0.19%
Anisotropy Function
The 2D anisotropy function values produced in this study for r = {0.4cm, 0.6cm, 1cm,
3.5cm, 6cm, 10cm} are presented in figure 4.3. These figures show good agreement with
consensus data. Notable differences can be seen at data points close to the long axis of the
source. The combined standard uncertainty for all data points are no larger than 1.47%














































GATE Taylor and Rogers
Figure 4.3: Anisotropy comparisons for (a) r = 0.4 cm, (b) r = 0.6 cm, (c) r = 1 cm, (d) r
= 3.5 cm, (e) r = 6 cm and (f) r = 10 cm.
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4.2 Monte Carlo Calibration factor
Presented in table 4.3 are dose rates estimations at two representations of P(r0, θ0) deter-
mined in GATE and ABV. Using these values and equation 3.10, the monte carlo calibration
factor calculated and applied in this study was,
f=1.15 x 1012 histories/second
where the combined uncertainty in f is 2.92% (k=2)
Table 4.3: Dose rate measured at multiple representations of P(r0, θ0) in GATE and ABV.
GATE ABV
D (Gy) U (k=1) Ḋ (Gy/history) D (Gy) Ḋ (Gy/second)
P(r, θ, φ) 2.34x10−4 1.03% 1.11 x 10−13 1.288 0.1288
P(r, θ, φ) 2.35x10−4 1.03% 1.11 x 10−13 1.288 0.1288
Mean 1.12x10−13 Mean 0.1288
4.3 GATE Vs Acuros BrachyVision Comparison
4.3.1 Point-to-Point Profile Comparison
Figures 4.4 - 4.9 present direct dose to medium profile comparison for each phantom setup
and differences at each data point as a ratio. The combined standard uncertainty for all
data points ≤16.7% (k=2). Profiles generated in ABV between -0.2 cm≤y≤0.2 cm are flat
and therefore comparisons were not made in this region.





























Figure 4.4: GATE versus ABV profile comparison for phantom 1, with (a) showing a direct
point-to-point comparison and (b) displaying the dose difference at each point as a ratio.
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Figure 4.5: GATE versus ABV profile comparison for phantom 2, with (a) showing a direct
point-to-point comparison and (b) displaying the dose difference at each point as a ratio.





























Figure 4.6: GATE versus ABV profile comparison for phantom 3, with (a) showing a direct
point-to-point comparison and (b) displaying the dose difference at each point as a ratio.





























Figure 4.7: GATE versus ABV profile comparison for phantom 4, with (a) showing a direct
point-to-point comparison and (b) displaying the dose difference at each point as a ratio.
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Figure 4.8: GATE versus ABV profile comparison for phantom 5, with (a) showing a direct
point-to-point comparison and (b) displaying the dose difference at each point as a ratio.





























Figure 4.9: GATE versus ABV profile comparison for phantom 6, with (a) showing a direct
point-to-point comparison and (b) displaying the dose difference at each point as a ratio.
4.3.2 1D Gamma Analysis
Presented in figure 4.10 are the gamma index values calculated at every point. A gamma
index pass criteria of 2%/1 mm gave pass rates of 43% for phantom 1, 86% for phantom
2, 57% for phantom 3 and 100% for phantoms 4, 5 and 6. A gamma index pass criteria of
2%/2 mm gave pass rates of 59%, 98% for phantom 2, 89% for phantom 3 and 100% for
phantoms 4, 5 and 6.
4.3.3 Correlation Analysis
For correlation analysis, profiles in all phantoms were separated and analysed as two separate
profiles (i.e. +y and -y). By doing this, comparisons were made only between points in the
same material. Pearson correlation coefficients (r) for all profiles are shown in table 4.4 with
corresponding p values. To visualize the Pearson correlation coefficients, plots of ABV doses



































Figure 4.10: 1D gamma analysis results for phantoms 1(a), 2(b), 3(c), 4(d), 5(e) and 6(f)
using a gamma criteria of 2%/1 mm and 2%/2 mm.
Table 4.4: Pearson correlation coefficients for correlation analyses done on every phantom,







1 0.9786 < 0.05 0.9816 < 0.05
2 0.9915 < 0.05 0.9924 < 0.05
3 0.9930 < 0.05 0.9908 < 0.05
4 0.9888 < 0.05 0.9883 < 0.05
5 0.9940 < 0.05 0.9940 < 0.05






































Figure 4.11: Visualisations of the Pearson Correlation Coefficients calculated for phantoms





Validation of the modelled source was achieved by first comparing simulated photon spectra
with results produced in a study conducted by Taylor and Rogers [1], and TG43 factors
with recommended consensus data published by Perez et al. [13].
5.1.1 Spectrum Comparisons
Energy weighted spectra comparisons show there is good agreement with Taylor and Rogers
results. Noticeable differences are seen at the lower end of the spectra which may be at-
tributed to the different Ir-192 spectra attached to the core of each source model. In addition,
an energy cut of 10 keV has been applied in all GATE simulations. The Ir192 spectrum used
by Taylor and Rogers was taken from work done by Duchemin and Coursol [72], whereas
this study used the spectrum provided by the NNDC [46]. A study done by Rivard et
al. [24] showed that spectra used in both studies have minimal affect on TG43 parameter
estimations. However, given that the NNDC spectrum is more recent and internationally
evaluated, Rivard et al. suggest the NNDC Ir-192 spectrum be used for all medical physics
applications.
5.1.2 TG43 Comparisons
TG43 parameters for the GammaMed Plus source have been extensively studied by both
Ballester et al. [2] and Taylor and Rogers [1]. Ballester et al. conducted their study
using Geant3 whereas Taylor and Rogers used EGSnrc. Although both studies produced
comparable results, Taylor and Rogers results for the radial dose function were noisy. Dose
rate constants reported in both studies were 1.118±0.003 cGy·h−1 ·U−1 [2] and 1.115±0.003
cGy · h−1 · U−1 [1], where the average of these two values is used as consensusΛ. Due to the
noisy results produced by Taylor and Rogers, Ballester et al. data was used as consensus
data for the remaining TG43 parameters (consensusgL(r) and consensusF(r, θ)).
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Perez et al. published a value of consensusΛ = 1.117 ± 0.004 cGy/hU for the DRC, while in
this study the dose rate constant was estimated as Λ = 1.123± 0.033 cGy/hU. The largest
sources of uncertainty in this studies best estimation of the DRC were,
• the statistical uncertainty (type A) in measuring the dose rate at P(r0, θ0), and
• the estimated uncertainty (type B) in interpolating between data points when esti-
mating the mass energy absorption coefficients for all energies.
The DRC estimated in this study is 0.57% higher than the consensus value but still agrees
within the uncertainties.
Radial dose function values estimated in this study are in good agreement with consensus
data values. All data points agreed within ±0.61%, with the largest differences being located
at distances equal to 0.2 cm and 10 cm. A study done by Perez et al. [73] showed there is a
relationship between phantom geometry and radial dose function and therefore a comparison
was also made with Taylor and Rogers radial dose function results. Comparisons with
Taylor and Rogers results agreed within ±0.29%, with the largest difference being located
at a distance equal to 6 cm. Phantom geometry used across all three studies are different,
with Ballester et al. using a 40 cm high solid cylinder with a 40 cm radius [74], Taylor and
Rogers using a 30 x 30 x 30 cm3 cube and a sphere with a 40 cm radius used in this study.
The key result in comparing all three sets of data is that values estimated in this study are
within the spread of estimations made in other certified studies.
Noticeable differences in anisotropy function comparisons were seen at points within 8 de-
grees of the source axis. Angles between 8 deg - 172 deg are in good agreement, with the
majority of data points agreeing within 1%. Large differences near the source axis can be
attributed to multiple factors. The first being a difference in source wire lengths modelled
in both studies. Ballester et al. used a source wire length of 6 cm, where as a 2 mm source
wire length was used in this study. Secondly, Ballester et al. scored dose instead of kerma.
By doing this, Ballester et al. were able to present more accurate results near the long axis
of the source [13]. Lastly, Ballester et al. included interpolated/extrapolated data for all
points within the source (including the source wire).
Overall, comparisons with consensus data are in good agreement. Dose rate constant, radial
dose function and for the most part anisotropy function estimations agree within 1%. These
results demonstrate that the physics, actors, VRT’s and source specifications have been
accurately defined. Therefore, the GMP source modelled using the GATE toolkit accurately
reflects what happens in the real world.
5.2 GATE vs BV Comparisons
The aim of this study was to assess the dose calculation accuracy of ABV in materials
relevant to HDR brachytherapy. With the source validated, comparisons of ABV and GATE
doses were executed using the following methods,
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• Point-to-point profile comparisons
• 1D gamma analysis
• Correlation analysis
This section will discuss some of the common themes highlighted across all phantom com-
parisons.
5.2.1 Point-to-Point Profile Comparison
GATE and ABV doses agreed within uncertainty for the majority of data points in all profile
comparisons (figure 4.4 - figure 4.9); however common trends seen in all case comparisons
are the large differences seen at distances close to the source (i.e. r≤0.6 cm) and in low
density materials such as lung and air.
Large differences observed at close distances may be attributed to multiple factors, with the
first being a lack of CPE. ABV assumes CPE exists at all points. In light of this, CPE may
not exist at points within ±0.6 cm of the source due to a nonuniform fluence [75], insufficient
build up and an increase or decrease in backscatter. With high density materials such as
stainless steel assigned to the source slab, differences in this region were reduced. Given the
attenuation properties of materials like stainless steel, less build up material is required to
reach CPE. Secondly, GATE and ABV doses may be pushed further apart due to voxel size
effects in high dose gradient regions. A study conducted by Taylor and Rogers [76] showed
that doses may be overestimated when using a large voxel calculation size.
Large differences were also seen when estimating doses in low density materials such as air
and lung. This is illustrated by comparing doses in phantoms 1 and 3 (figure 4.4 and figure
4.6). ABV assumes all secondary electrons ranges are smaller than the voxel calculation
size and deposit their energy locally (figure 5.1 [77]). Therefore in the context of cavity
theory, ABV applies large cavity theory assumptions [8]. Stopping power data published
by NIST [78] show that electrons with an initial kinetic energy of 0.3 MeV have a range of
up to 0.842 mm in water, 3.27 mm in lung and 794 mm in air. Therefore, electron ranges
will be much larger than the voxel calculation grid size and as a result Kcoll < D. Energy
deposited within these regions would be better described using small cavity theory, where
dose is more accurately calculated using fluence and stopping powers [8]. Following these
results, clinical recommendations would be to ensure that bolus, gauze and bladder filling
protocols are utilised to reduce any gaps in and around the treatment area.
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Figure 5.1: A schematic demonstrating large cavity theory, where secondary electron ranges
are much smaller than the detection volume and deposit there dose locally.
5.2.2 1D Gamma Analysis
The most straightforward method for comparing profiles is a point-to-point comparison.
However, it is method that can be very sensitive in high dose gradient regions [79]. As
mentioned above, large differences were seen in all cases at points within close proximity of
the source. Given the high dose gradients surrounding a brachytherapy source, a gamma
analysis was applied to all profiles to collectively quantify the dose differences and spatial
misalignment’s at each data point.
The AAPM’s report of TG186 [15] recognises the necessity of defining a gamma criteria
specifically for brachytherapy and therefore proposed a gamma analysis pass criteria of
2%/2 mm with a ≥99% pass rate. TG186 also recognises that there is limited research on
gamma criteria for brachytherapy and therefore understand that their proposed pass criteria
may need to be adjusted depending on the case. Given the simplicity of the phantoms used
in this study, a stricter gamma index criterion of 2%/1mm with a ≥ 99% was also used.
Among the 6 phantoms, phantoms 4, 5 and 6 produce gamma index pass rates of 100% for
both pass criterion’s used. However, phantoms 1, 2 and 3 produced varying results. Using
a gamma index pass criteria of 2%/1 mm, phantoms 1, 2 and 3 produced passing rates
of 43%, 86% and 57% respectively. Using TG186’s proposed criteria, pass rates increased.
Phantoms 1, 2 and 3 pass rates increased from 43%, 86% and 57% to 59%, 98% and 89%
respectively. Given ABV’s inability to accurately estimate doses in low density materials,
low gamma index pass rates were to be expected for phantoms 1 and 3. The key finding in
the gamma analysis results is that even with high density materials producing an excess in
backscatter near the source, the spatial distribution of dose is within ±2 mm.
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5.3 Clinical Implications
Within a clinical setting, the results presented in this study show that ABV can be used,
but with caution. Simulated results show that ABV is unable to accurately calculate dose
within and beyond low density materials. This is illustrated in phantoms 1 and 3 (figures 4.4
and 4.6). However, ABV demonstrates good accuracy when calculating doses in anatomical
and applicator materials such as bone, cartilage, muscle, adipose, pmma, peek, titanium
and stainless steel.
Given ABV demonstrates inaccuracies in low density materials, brachytherapy procedures
should include identifying and minimising all air gaps immediately surrounding the source
and volumes of interest. For gynaecological and prostate brachytherapy, the most common
sites treated with brachytherapy at the WRCC, this is achieved using Vaseline gauze and
bladder filling protocols [80, 81, 82].
Despite ABV’s limitation in low density materials, it provides noticeable improvements when
calculating dose in high density materials like stainless steel. This is illustrated in figure
5.2. For dose calculated in and beyond stainless steel, differences between GATE and TG43
doses ranged between -3.03 - -20.48 %, and gave an average difference of -8.59%; whereas
differences between GATE and ABV doses ranged between -15.71 - 5.83 %, and gave an
average difference of 0.8%. Therefore, this study’s results showed that ABV is capable
of providing more accurate dose calculations for plans including gynaecological applicators
such the Fletcher-suit system [83].


















In first part of this study, Varian’s Ir192 GammaMed Plus HDR source was modelled using
the GATE MC toolkit. Geometry information published by Lopez et al. [45] and energy
spectrum information provided by the NNDC [46] were combined to construct the source.
Photon spectra and TG43 factors simulated in this study were compared to data published
by Taylor and Rogers [1] Ballester et al. [2] and Perez et al. [13]. Output spectrum
comparisons showed good agreement with minor differences seen at the lower end of the
spectrum. TG43 comparisons also showed good agreement, with the DRC, radial dose
function and anisotropy data points located between 8 deg - 172 deg agreeing within 1%.
The second part of this study was to compare GATE and ABV doses in a variety of materials
relevant to HDR brachytherapy. Point-to-point comparisons showed large difference at
distances close to the source (i.e. r ≤ 0.6 cm). Notable differences were also observed in low
density materials such as lung and air. It was proposed that these large differences arise
due to a lack of CPE and secondary electrons escaping their local voxels.
1D gamma index analyses were evaluated for all phantoms. Using a gamma analysis pass
criteria of 2%/1 mm produced pass rates for phantoms 1, 2, 3, 4, 5, 6 of 45%, 84%, 55%,
100%, 100% and 100% respectively. Using TG186’s recommended pass criteria of 2%/2 mm
produced increased pass rates of 59%, 100% and 88% for phantoms 1, 2 and 3 respectively.
Although point-to-point comparisons showed large differences in the near source region,
gamma analysis results show that the spatial distribution of dose in this region is within 2
mm.
Pearson correlation coefficients and their correlated p-values suggest that statistically there
is no significant difference between MC and ABV doses. However, caution should be taken
when interpreting correlation analysis due to its inability to detect causation.
The results presented in this study demonstrate that when applied correctly, ABV can
produce accurate dose calculations. Caution must be taken when volumes of low density
material are present, as ABV will underestimate doses in and beyond these regions. In
contrast to this, ABV is highly capable of calculating doses in high density materials like
steel and and bone. The clinical implications of this would mean that when compared to
TG43, ABV would provide more accurate results.
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6.1 Future Work
The results given in this study have shown that the GMP source has been modelled accu-
rately and that ABV calculated doses are comparable with MC calculated doses except for
in regions immediately surrounding the source. However, more research is required before
ABV can be implemented clinically. Future work to improve and extend this study should
firstly aim to develop a phantom for acquiring 2D dose distributions and point dose measure-
ments. This will provide a means to compare simulated results with physical measurements
and show that simulated results reflect what is happening in the real world. Following on
from this, further comparisons must be made between MC and ABV. Comparisons need to
be extended from 1D to 2D, and then to 3D using anatomical CT data sets that include
target volumes and applicators.
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A.1.5 Material Compisition Data
[Elements]
Hydrogen: S= H ; Z= 1. ; A= 1.01 g/mole
Helium: S= He ; Z= 2. ; A= 4.003 g/mole
Lithium: S= Li ; Z= 3. ; A= 6.941 g/mole
Beryllium: S= Be ; Z= 4. ; A= 9.012 g/mole
Boron: S= B ; Z= 5. ; A= 10.811 g/mole
Carbon: S= C ; Z= 6. ; A= 12.01 g/mole
Nitrogen: S= N ; Z= 7. ; A= 14.01 g/mole
Oxygen: S= O ; Z= 8. ; A= 16.00 g/mole
Fluorine: S= F ; Z= 9. ; A= 18.998 g/mole
Neon: S= Ne ; Z= 10. ; A= 20.180 g/mole
Sodium: S= Na ; Z= 11. ; A= 22.99 g/mole
Magnesium: S= Mg ; Z= 12. ; A= 24.305 g/mole
Aluminium: S= Al ; Z= 13. ; A= 26.98 g/mole
Silicon: S= Si ; Z= 14. ; A= 28.09 g/mole
Phosphor: S= P ; Z= 15. ; A= 30.97 g/mole
Sulfur: S= S ; Z= 16. ; A= 32.066 g/mole
Chlorine: S= Cl ; Z= 17. ; A= 35.45 g/mole
Argon: S= Ar ; Z= 18. ; A= 39.95 g/mole
Potassium: S= K ; Z= 19. ; A= 39.098 g/mole
Calcium: S= Ca ; Z= 20. ; A= 40.08 g/mole
Scandium: S= Sc ; Z= 21. ; A= 44.956 g/mole
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Titanium: S= Ti ; Z= 22. ; A= 47.867 g/mole
Vandium: S= V ; Z =23. ; A= 50.942 g/mole
Chromium: S= Cr ; Z= 24. ; A= 51.996 g/mole
Manganese: S= Mn ; Z= 25. ; A= 54.938 g/mole
Iron: S= Fe ; Z= 26. ; A= 55.845 g/mole
Cobalt: S= Co ; Z= 27. ; A= 58.933 g/mole
Nickel: S= Ni ; Z= 28. ; A= 58.693 g/mole
Copper: S= Cu ; Z= 29. ; A= 63.39 g/mole
Zinc: S= Zn ; Z= 30. ; A= 65.39 g/mole
Gallium: S= Ga ; Z= 31. ; A= 69.723 g/mole
Germanium: S= Ge ; Z= 32. ; A= 72.61 g/mole
Yttrium: S= Y ; Z= 39. ; A= 88.91 g/mole
Silver: S= Ag ; Z= 47. ; A= 107.868 g/mole
Cadmium: S= Cd ; Z= 48. ; A= 112.41 g/mole
Tin: S= Sn ; Z= 50. ; A= 118.71 g/mole
Antimony: S= Sb ; Z= 51. ; A= 121.76 g/mole
Tellurium: S= Te ; Z= 52. ; A= 127.6 g/mole
Iodine: S= I ; Z= 53. ; A= 126.90 g/mole
Cesium: S= Cs ; Z= 55. ; A= 132.905 g/mole
Gadolinium: S= Gd ; Z= 64. ; A= 157.25 g/mole
Lutetium: S= Lu ; Z= 71. ; A= 174.97 g/mole
Tungsten: S= W ; Z= 74. ; A= 183.84 g/mole
Gold: S= Au ; Z= 79. ; A= 196.967 g/mole
Thallium: S= Tl ; Z= 81. ; A= 204.37 g/mole
Lead: S= Pb ; Z= 82. ; A= 207.20 g/mole
Bismuth: S= Bi ; Z= 83. ; A= 208.98 g/mole
Uranium: S= U ; Z= 92. ; A= 238.03 g/mole
Molybdenum: S= Mo ; Z= 42. ; A= 95.94 g/mole
Iridium: S= Ir ; Z= 77 ; A= 192.217 g/mole
Platinum: S= Pt ; Z= 78 ; A= 195.078 g/mole
[Materials]
Water: d=1 g/cm3 ; n=1
+el: name=Hydrogen ; f=0.111894
+el: name=Oxygen ; f=0.888106
Seed192: d=22.42 g/cm3 ; n=1
+el: name=Iridium ; n=1
TitaniumBV: d=4.42 g/cm3 ; n=3
+el: name=Aluminium ; f=0.06
+el: name=Titanium ; f=0.9
+el: name=Vandium ; f=0.04
Vacuum: d=0.000001 mg/cm3 ; n=1
+el: name=Hydrogen ; n=1
AirTG43U: d=0.0012 g/cm3 ; n=4
+el: name=Nitrogen ; f=0.750325
+el: name=Oxygen ; f=0.236077
+el: name=Argon ; f=0.012743
+el: name=Carbon ; f=0.000123
+el: name=Hydrogen ; f=0.000732
LungBV: d=0.26 g/cm3 ; n=13
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+el: name=Hydrogen ; f=0.101278
+el: name=Carbon ; f=0.102310
+el: name=Nitrogen ; f=0.028650
+el: name=Oxygen ; f=0.757072
+el: name=Sodium ; f=0.001840
+el: name=Magnesium ; f=0.000730
+el: name=Phosphor ; f=0.000800
+el: name=Sulfur ; f=0.002250
+el: name=Chlorine ; f=0.002660
+el: name=Potassium ; f=0.001940
+el: name=Calcium ; f=0.000090
+el: name=Iron ; f=0.000370
+el: name=Zinc ; f=0.000010
MuscleBV: d=1.05 g/cm3 ; n=13
+el: name=Hydrogen ; f=0.100637
+el: name=Carbon ; f=0.10783
+el: name=Nitrogen ; f=0.027680
+el: name=Oxygen ; f=0.754773
+el: name=Sodium ; f=0.00075
+el: name=Magnesium ; f=0.000190
+el: name=Phosphor ; f=0.0018
+el: name=Sulfur ; f=0.00241
+el: name=Chlorine ; f=0.00079
+el: name=Potassium ; f=0.00302
+el: name=Calcium ; f=0.00003
+el: name=Iron ; f=0.00004
+el: name=Zinc ; f=0.00005
BoneBV: d=1.92 g/cm3 ; n=9
+el: name=Hydrogen ; f=0.047234
+el: name=Carbon ; f=0.14433
+el: name=Nitrogen ; f=0.04199
+el: name=Oxygen ; f=0.446096
+el: name=Magnesium ; f=0.0022
+el: name=Phosphor ; f=0.10497
+el: name=Sulfur ; f=0.00315
+el: name=Calcium ; f=0.20993
+el: name=Zinc ; f=0.0001
AdiposeBV: d=0.92 g/cm3 ; n=11
+el: name=Hydrogen ; f=0.119477
+el: name=Carbon ; f=0.637240
+el: name=Nitrogen ; f=0.007970
+el: name=Oxygen ; f=0.232333
+el: name=Sodium ; f=0.0005
+el: name=Magnesium ; f=0.00002
+el: name=Phosphor ; f=0.00016
+el: name=Sulfur ; f=0.00073
+el: name=Chlorine ; f=0.00119
+el: name=Potassium ; f=0.00032
+el: name=Calcium ; f=0.00002
+el: name=Iron ; f=0.00002
+el: name=Zinc ; f=0.00002
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CartilageBV: d=1.10 g/cm3 ; n=11
+el: name=Hydrogen ; f=0.096
+el: name=Carbon ; f=0.099
+el: name=Nitrogen ; f=0.022
+el: name=Oxygen ; f=0.744
+el: name=Sodium ; f=0.005
+el: name=Phosphor ; f=0.022
+el: name=Sulfur ; f=0.009
+el: name=Chlorine ; f=0.003
+el: name=Argon ; f=0.0
+el: name=Potassium ; f=0.0
+el: name=Calcium ; f=0.0
316L: d=8.03 g/cm3 ; n=10;
+el: name=Carbon ; f=0.0003
+el: name=Nitrogen ; f=0.001
+el: name=Silicon ; f=0.0075
+el: name=Phosphor ; f=0.00045
+el: name=Sulfur ; f=0.0003
+el: name=Chromium ; f=0.17
+el: name=Manganese ; f=0.02
+el: name=Iron ; f=0.65545
+el: name=Nickel ; f=0.12
+el: name=Molybdenu ; f=0.025
304: d=5.6 g/cm3 ; n=9
+el: name=Carbon ; f=0.0008
+el: name=Nitrogen ; f=0.001
+el: name=Silicon ; f=0.0075
+el: name=Phosphor ; f=0.00045
+el: name=Sulfu ; f=0.0003
+el: name=Chromium ; f=0.19
+el: name=Manganese ; f=0.02
+el: name=Iron ; f=0.68745
+el: name=Nickel ; f=0.0925
SSBV: d=8 g/cm3 ; n=7
+el: name=Carbon ; f=0.0008
+el: name=Silicon ; f=0.01
+el: name=Phosphor ; f=0.00045
+el: name=Chromium ; f=0.19
+el: name=Manganese ; f=0.02
+el: name=Iron ; f=0.68375
+el: name=Nickel ; f=0.095
PeekBV: d=1.31 g/cm3 ; n=3
+el: name=Hydrogen ; f=0.041954
+el: name=Carbon ; f=0.791557
+el: name=Oxygen ; f=0.166489
PMMABV: d=1.19 g/cm3 ; n=3
+el: name=Hydrogen ; f=0.080542
+el: name=Carbon ; f=0.59984
+el: name=Oxygen ; f=0.319618
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µen/ρ for 0.001 MeV ≤ E ≤ 1.5 MeV
ABV
Gate
Figure A.1: Mass energy absorption coefficient plot for photons with energies 0.001 MeV ≤
E ≤ 1.5 MeV.
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A.2 Tables and Figures
A.2.1 Air KERMA Strength Sk and Dose Rate Constant Λ
A.2.2 Geometry Function
Figure A.2: Geometry function
A.2.3 Radial Dose Function
Table A.1: Ring dimensions used for g(r) measurements
Ring Dimensions
r (cm) OD (cm) ID (cm) Height (cm) Volume
(cm3)
0.2 0.195 0.205 0.1 0.126
0.25 0.255 0.245 0.1 0.157
0.5 0.505 0.495 0.1 0.314
0.75 0.755 0.745 0.1 0.471
1 1.005 0.995 0.1 0.628
1.5 1.525 1.475 0.5 23.562
2 2.025 1.975 0.5 31.416
3 3.025 2.975 0.5 47.124
4 4.025 3.975 0.5 62.832
5 5.025 4.975 0.5 78.540
6 6.05 5.95 1 376.991
8 8.05 7.95 1 502.655
10 10.05 9.95 1 628.319
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A.2.4 2D Anisotropy Function
Table A.2: Cylinder dimensions used for F(r = 4mm, θ) measurements, where h=0.1mm
Cylinder Dimensions for r = 4 mm
θ OD (mm) ID (mm) Z = r Cos(θ) (mm)
90 ± 88 0.19 0.09 ∓3.998
90 ± 86 0.33 0.23 ∓3.990
90 ± 84 0.47 0.37 ∓3.978
90 ± 82 0.61 0.51 ∓3.961
90 ± 80 0.74 0.64 ∓3.939
90 ± 70 1.42 1.32 ∓3.759
90 ± 60 2.05 1.95 ∓3.464
90 ± 50 2.62 2.52 ∓3.064
90 ± 40 3.11 3.01 ∓2.571
90 ± 30 3.51 3.41 ∓2.000
90 ± 20 3.81 3.71 ∓1.368
90 ± 10 3.99 3.89 ∓0.695
90 ± 0 4.05 3.95 0
90 ± 90 Cube dimensions 0.1 mm x 0.1 mm x 0.1 mm
Table A.3: Cylinder dimensions used for F(r = 6mm, θ) measurements, where h=0.1mm
Cylinder Dimensions for r = 6 mm
θ OD (mm) ID (mm) Z = r Cos(θ) (mm)
90 ± 88 0.26 0.16 ∓5.996
90 ± 86 0.47 0.37 ∓5.985
90 ± 84 0.68 0.58 ∓5.967
90 ± 82 0.89 0.79 ∓5.942
90 ± 80 1.09 0.99 ∓5.909
90 ± 70 2.10 2.00 ∓5.638
90 ± 60 3.05 2.95 ∓5.196
90 ± 50 3.91 3.81 ∓4.596
90 ± 40 4.65 4.55 ∓3.857
90 ± 30 5.25 5.15 ∓3.000
90 ± 20 5.69 5.59 ∓2.052
90 ± 10 5.96 5.86 ∓1.042
90 ± 0 6.05 5.95 0
90 ± 90 Cube dimensions 0.1 mm x 0.1 mm x 0.1 mm
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Table A.4: Cylinder dimensions used for F(r = 10mm, θ) measurements, where h=0.1mm
Cylinder Dimensions for r = 10 mm
θ OD (mm) ID (mm) Z = r Cos(θ) (mm)
90 ± 88 0.4 0.3 ∓9.994
90 ± 86 0.75 0.65 ∓9.976
90 ± 84 1.1 1.00 ∓9.945
90 ± 82 1.44 1.34 ∓9.903
90 ± 80 1.79 1.69 ∓9.848
90 ± 70 3.47 3.37 ∓9.397
90 ± 60 5.05 4.95 ∓8.660
90 ± 50 6.48 6.38 ∓7.660
90 ± 40 7.71 7.61 ∓6.428
90 ± 30 8.71 8.61 ∓5.000
90 ± 20 9.45 9.35 ∓3.420
90 ± 10 9.90 9.80 ∓1.736
90 ± 0 10.05 9.98 0
90 ± 90 Cube dimensions 0.1 mm x 0.1 mm x 0.1 mm
Table A.5: Cylinder dimensions used for F(r = 35mm, θ) measurements, where h=0.5mm
Cylinder Dimensions for r = 35 mm
θ OD (mm) ID (mm) Z = r Cos(θ) (mm)
90 ± 88 1.47 0.97 ∓34.979
90 ± 86 2.69 2.17 ∓34.915
90 ± 84 3.91 3.41 ∓34.808
90 ± 82 5.12 4.62 ∓34.659
90 ± 80 6.33 5.83 ∓34.468
90 ± 70 12.22 11.72 ∓32.889
90 ± 60 17.75 17.25 ∓30.311
90 ± 50 22.75 22.25 ∓26.812
90 ± 40 27.06 26.56 ∓22.498
90 ± 30 30.56 30.06 ∓17.5
90 ± 20 33.14 32.64 ∓11.971
90 ± 10 34.72 34.22 ∓6.078
90 ± 0 35.25 34.75 0
90 ± 90 Cube dimensions 0.5 mm x 0.5 mm x 0.5 mm
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Table A.6: Cylinder dimensions used for F(r = 60mm, θ) measurements, where h=1mm
Cylinder Dimensions for r = 60 mm
θ OD (mm) ID (mm) Z = r Cos(θ) (mm)
90 ± 88 2.59 1.59 ∓59.963
90 ± 86 4.69 3.69 ∓59.854
90 ± 84 6.77 5.77 ∓59.671
90 ± 82 8.85 7.85 ∓59.416
90 ± 80 10.92 9.92 ∓59.088
90 ± 70 21.00 20.02 ∓56.382
90 ± 60 30.50 29.50 ∓51.962
90 ± 50 39.07 38.07 ∓45.963
90 ± 40 46.46 45.46 ∓38.567
90 ± 30 52.46 51.46 ∓30.00
90 ± 20 56.88 55.88 ∓20.521
90 ± 10 59.59 58.59 ∓10.419
90 ± 0 60.50 59.50 0
90 ± 90 Cube dimensions 1 mm x 1 mm x 1 mm
Table A.7: Cylinder dimensions used for F(r = 100mm, θ) measurements, where h=1mm
Cylinder Dimensions for r = 100 mm
θ OD (mm) ID (mm) Z = r Cos(θ) (mm)
90 ± 88 3.99 2.99 ∓99.939
90 ± 86 7.48 6.48 ∓99.756
90 ± 84 10.95 9.95 ∓99.452
90 ± 82 14.42 13.42 ∓99.027
90 ± 80 17.86 16.86 ∓98.481
90 ± 70 34.70 33.70 ∓93.969
90 ± 60 50.50 49.50 ∓86.603
90 ± 50 64.78 63.78 ∓76.064
90 ± 40 77.10 76.10 ∓64.279
90 ± 30 87.10 86.10 ∓50.000
90 ± 20 94.47 93.47 ∓34.202
90 ± 10 98.98 97.98 ∓517.365
90 ± 0 100.50 99.5 0
90 ± 90 Cube dimensions 1 mm x 1 mm x 1 mm
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